Hodgkin's lymphoma survivors may have increased risk for cardiovascular disease
the ONA take:
According to a new study published online in JAMA Internal Medicine, researchers in the Netherlands have found that survivors of Hodgkin's lymphoma may be at a higher risk for cardiovascular diseases.
For the study, researchers evaluated 2,524 Dutch patients diagnosed with Hodgkin's lymphoma at younger than 51 years of age who had survived for 5 years after diagnosis. Patients had received mediastinal radiotherapy and anthracycline-containing chemotherapy.
Results showed that Hodgkin's lymphoma survivors had a 4-fold to 7-fold increased risk for coronary heart disease or heart failure 35 years or more after cancer treatment compared with the general population.
Researchers also found that mediastinal radiotherapy increased the risk for coronary heart disease, valvular heart disease, and heart failure, while those who received anthracycline-containing chemotherapy had a higher risk for valvular heart disease and heart failure as first events events versus patients who did not receive those treatments.
The findings suggest that "treating physicians and patients should be aware of the persistently increased risk of cardiovascular diseases throughout life, and the results of our study may direct guidelines for follow-up of patients with HL."
Survivors of Hodgkin's lymphoma may be at a higher risk for cardiovascular diseases.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|